江西富祥药业股份有限公司 2025 年 1-6 月 非经营性资金占用及其他关联资金往来情况汇总表 江西富祥药业股份有限公司 非经营性资金占用及其他关联资金 往来情况的专项报告 2025年半年度 单位：元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的 | 2025 年期初占用 | 2025 年 1-6 月占用 累计发生金额（不含 | 2025 年 1-6 月 占用资金的利 | 2025 年 1-6 月偿 | 2025 年 6 月期末 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 会计科目 | 资金余额 | 利息） | 息(如有) | 还累计发生金额 | 占用资金余额 | 因 | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小计 | | | | ...

Core Viewpoint - The company, Fuxiang Pharmaceutical, is focusing on the development of microbial new protein as a strategic initiative to enhance its market position and contribute to national food security and carbon reduction goals [2][6][9]. Company Overview - Fuxiang Pharmaceutical was established in 2002 and listed on the Shenzhen Stock Exchange in 2015. It is recognized as a national "specialized, refined, distinctive, and innovative" small giant enterprise and a high-tech enterprise in China [4]. - The company specializes in the research, production, and sales of active pharmaceutical ingredients and intermediates, with a recent focus on extending its capabilities into microbial new protein applications [4][5]. Strategic Focus on Microbial New Protein - The company has identified microbial new protein as a key growth area due to its high efficiency, sustainability, and health benefits, including being high in protein, dietary fiber, low in sugar, low in fat, and cholesterol-free [5][6]. - The production of microbial new protein is seen as a solution to the challenges of traditional protein sources, particularly in light of increasing global protein demand and reliance on imported soybean [6]. Market Potential and Growth Projections - The global market for alternative proteins, including microbial fermentation proteins, is projected to reach at least $290 billion by 2035, with microbial proteins expected to capture 22% of this market share [7]. - Fuxiang Pharmaceutical has established itself as a pioneer in the microbial new protein sector, achieving a production capacity of 1,200 tons per year and is currently developing a project with an annual capacity of 200,000 tons [9]. Commitment to Dual Strategy - The company emphasizes the importance of maintaining its core pharmaceutical business while developing new protein lines, ensuring a balanced approach to growth and stability [7][9]. - The strategic focus on microbial new protein aligns with national goals for food security and carbon neutrality, positioning the company as a contributor to sustainable development [6][9].

Group 1 - The core viewpoint of the news is the significant rise in virus prevention concept stocks, particularly in response to the release of the 2025 treatment plan for Chikungunya virus, which has led to increased investor interest in related companies [1][2] - Companies such as Lide Man, Lianhuan Pharmaceutical, and Rejing Bio have seen substantial stock price increases, with Lide Man reaching a 20% limit up and Lianhuan Pharmaceutical achieving a nearly 10% increase [1][2] - The treatment plan emphasizes preventive measures against Chikungunya virus, including mosquito control and personal protective measures, highlighting the ongoing public health concern and the lack of available vaccines in China [1] Group 2 - Specific stock performance data shows Lide Man with a 20.03% increase, Lianhuan Pharmaceutical with a 9.98% increase, and Rejing Bio with a 9.25% increase, indicating strong market reactions [2] - Year-to-date performance reveals that Rejing Bio has surged by 244.50%, while Lianhuan Pharmaceutical has increased by 97.68%, showcasing the potential for continued growth in the sector [2] - Other companies such as Zhongsheng Pharmaceutical and Maiwei Niuwu also experienced notable gains, further indicating a broader trend in the virus prevention sector [1][2]

Group 1 - The core viewpoint of the news highlights a surge in virus prevention concept stocks, particularly in response to the release of the 2025 treatment plan for Chikungunya virus, which has led to significant stock price increases for several companies in the pharmaceutical sector [1][2] - Companies such as Lide Man and Lianhuan Pharmaceutical saw their stock prices rise by 20% and nearly 10% respectively, indicating strong market interest and potential investment opportunities in the sector [2] - The news also mentions that there is currently no available vaccine for the Chikungunya virus in China, which may drive demand for preventive measures and related pharmaceutical products [1] Group 2 - Specific stock performance data shows that Hotgen Biotech increased by over 9%, while Zhongsheng Pharmaceutical rose by over 7%, reflecting a broader trend of growth among virus prevention stocks [1][2] - The total market capitalization of Lide Man is reported at 4.597 billion, while Lianhuan Pharmaceutical stands at 5.538 billion, indicating substantial company valuations in the context of the current market dynamics [2] - Year-to-date performance shows that Hotgen Biotech has increased by 244.50%, suggesting a strong upward trend in investor confidence and market performance for this company [2]

北京市中伦律师事务所 关于江西富祥药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：江西富祥药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受江西富祥药业股份有限公 司（以下简称"公司"）委托，指派律师见证公司 2025 年第二次临时股东大会 （以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》等相关法律、法规、规章、规范性文件及《江西富祥药 业股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东大会 的相关事项进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见书所认定的事实真实、准确、完整，所 发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-053 江西富祥药业股份有限公司 第五届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》《公司章程》等有关规定，公司第五届董事会下设战略委员会、审计 委员会、薪酬与考核委员会、提名委员会，公司董事会选举下列人员组成公司第五届 董事会专门委员会，任期三年，自本次董事会审议通过之日起至第五届董事会届满之 日止。具体情况如下： 一、董事会会议召开情况 江西富祥药业股份有限公司（以下简称"公司"）第五届董事会第一次会议于 2025 年第二次临时股东大会选举产生第五届董事会成员后，经全体董事同意豁免会议通知 时间要求，以电话、口头等方式向全体董事送达。本次会议于 2025 年 7 月 14 日以现 场的方式在景德镇市昌江区鱼丽工业区 2 号公司三楼会议室举行。 会议应出席董事 7 人，实际出席的董事 7 人。会议由董事长包建华主持。会议召 开和表决程序符合《中华人民共和国公司法》等法律、法规及 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-052 江西富祥药业股份有限公司 2025年第二次临时股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 会议的召开及表决等程序符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 2、会议出席情况 股东出席的总体情况： 通过现场和网络投票的股东 130 人，代表股份 124,628,238 股，占公司有表决权 股份总数的 23.1372％。其中：通过现场投票的股东 7 人，代表股份 109,302,500 股， 占公司有表决权股份总数的 20.2920％。通过网络投票的股东 123 人，代表股份 15,325,738 股，占公司有表决权股份总数的 2.8452％。 中小股东出席的总体情况： 通过现场和网络投票的中小股东 123 人，代表股份 15,325,738 股，占公司有表决 权股份总数的 2.8452％。其中：通过现场投票的中小股东 0 人 ...

江西富祥药业股份有限公司（以下简称"公司"）于2025年7月14日召开2025年 第二次临时股东大会、第五届董事会第一次会议，完成了董事会换届选举及高级管理 人员、审计负责人、证券事务代表的聘任，现将相关情况公告如下： 证券代码：300497 证券简称：富祥药业 公告编号：2025-054 江西富祥药业股份有限公司 关于完成董事会换届选举及聘任高级管理人员、审计负责人和证券 事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、公司第五届董事会及专门委员会组成情况 1、董事长：包建华先生 2、董事会成员： （1）非独立董事：包建华先生、JIZU JOHN CHENG（程健祖）先生、李惠跃先 生、戴贞亮先生 （2）独立董事：刘洪先生、陈祥强先生、计小青女士 3、董事会各专门委员会组成情况 （1）战略委员会：包建华先生（主任委员）、JIZU JOHN CHENG（程健祖）先 生、刘洪先生； （2）审计委员会：计小青女士（主任委员）、戴贞亮先生、陈祥强先生； （3）薪酬与考核委员会：陈祥强先生（主任委员）、刘洪先生、李惠跃先生； （4）提名委员会：刘洪 ...

Core Points - The document outlines the insider information management system of Jiangxi Fuxiang Pharmaceutical Co., Ltd, aiming to ensure confidentiality and compliance with relevant laws and regulations [1][2][12] - The board of directors is responsible for managing insider information, with the chairman as the main person in charge and the board secretary handling the registration of insider information [1][2] Group 1: Insider Information Definition - Insider information refers to non-public information that significantly impacts the company's operations, finances, or market price of its securities [5][6] - Examples of insider information include major changes in equity structure, significant investments, important contracts, major debts, and changes in management [6][7][8] Group 2: Responsibilities of Insider Information Holders - Company directors, senior management, and other relevant personnel must maintain confidentiality and cooperate with the board secretary in registering insider information [2][3] - Insider information holders are prohibited from leaking information or trading based on insider knowledge before it is publicly disclosed [2][3][10] Group 3: Registration and Record-Keeping - The company must accurately record all individuals who have access to insider information before it is disclosed, including their names, positions, and the nature of the information [5][6] - A detailed record of the process leading to significant corporate actions must be maintained, including timelines and involved personnel [11][12] Group 4: Confidentiality Management and Accountability - Insider information holders are required to sign confidentiality agreements and are subject to penalties for violations, including potential legal action [10][11] - The company must conduct self-inspections regarding insider trading activities and report any violations to regulatory authorities [9][10]

Core Viewpoint - The document outlines the investor relations management system of Jiangxi Fuxiang Pharmaceutical Co., Ltd., emphasizing the importance of communication between the company and its investors to enhance corporate governance and maximize shareholder value [2][3]. Summary by Sections General Principles - The purpose of the investor relations management is to facilitate communication with investors, enhance their understanding of the company, and promote a culture of respect and service towards investors [2][3]. - The management work must adhere to principles of fairness, transparency, and compliance with relevant laws and regulations [3][4]. Objectives and Basic Principles - The objectives include fostering a positive relationship with investors, establishing a stable investor base, and increasing transparency in information disclosure [6][7]. - Basic principles include compliance, equality, proactivity, and integrity in investor relations activities [7][8]. Management Targets and Communication Content - The management targets include investors, securities analysts, and other relevant stakeholders [8]. - Key communication content includes the company's development strategy, financial status, operational information, and responses to investor inquiries [8][9]. Communication Methods - Various communication methods are employed, such as regular reports, annual meetings, one-on-one communications, and online platforms to ensure broad and efficient engagement with investors [10][11]. - The company is committed to equal treatment of all investors, particularly small and medium-sized investors, during communication activities [11][12]. Management Structure - The board secretary is designated as the head of investor relations management, supported by the board office, which is responsible for organizing and planning investor relations activities [27][28]. - Employees involved in investor relations must possess comprehensive knowledge of the company and relevant legal frameworks [28][29]. Compliance and Record Keeping - The company must avoid disclosing undisclosed significant information during investor relations activities and maintain a complete record of all investor interactions [28][29]. - A detailed record of investor relations activities must be compiled and made available to ensure transparency and accountability [29][30]. Training and Communication Channels - The company is required to provide training on investor relations management to its employees, especially senior management [31][32]. - A dedicated investor consultation hotline must be established to facilitate communication and address investor concerns promptly [31][32].